<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112709">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02008266</url>
  </required_header>
  <id_info>
    <org_study_id>ML25384</org_study_id>
    <nct_id>NCT02008266</nct_id>
  </id_info>
  <brief_title>Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis</brief_title>
  <official_title>Case Study of the Treatment of Early Rheumatoid Arthritis in Algerian Patients in Both the Private and Public Healthcare Sectors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <authority>Algeria: Ministère de la Santé de la Population et de la Réforme Hospitalière</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-interventional, descriptive, cross-sectional and multicenter study will examine the
      treatment of rheumatoid arthritis progressing for less than two years in the Algerian
      population. Current drug therapy as well as disease status and patient function will be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Describe medications used in the treatment of rheumatoid arthritis with &lt; 2 years' progression.</measure>
    <time_frame>Single observational visit [Day 1]</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure disease activity using DAS 28 assessment.</measure>
    <time_frame>Single observational visit [Day 1]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess joint damage using the modified SHARP method.</measure>
    <time_frame>Single observational visit [Day 1]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess functional status of patients using the Health Assessment Questionnaire (HAQ).</measure>
    <time_frame>Single observational visit [Day 1]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">532</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patients with Rheumatoid Arthritis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Rheumatoid Arthritis that has been progressing for &gt; 3 months and &lt; 2 years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis progressing for &lt; 2 years.

        Exclusion Criteria:

          -  Rheumatoid arthritis progressing for &lt; 3 months.

          -  Rheumatoid arthritis onset at &lt; 18 years of age.

          -  Participation in another clinical study.

          -  Rheumatoid arthritis related connective tissue disorder.

          -  Any neuropsychological disorders.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 6, 2013</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
